EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+17.74%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.94B
AUM Growth
+$3.94B
(+2.3%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-3.48%
Top 10 Holdings %
Top 10 Hldgs %
61.38%
Holding
66
New
15
Increased
8
Reduced
4
Closed
9
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$141M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$100M |
| 3 |
CRISPR Therapeutics
CRSP
|
$94.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$76.5M |
| 5 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$43.3M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$435M |
| 2 |
argenx
ARGX
|
$115M |
| 3 |
Edgewise Therapeutics
EWTX
|
$40.9M |
| 4 |
Spyre Therapeutics
SYRE
|
$19.1M |
| 5 |
Revolution Medicines
RVMD
|
$3.8M |
Sector Composition
| 1 | Healthcare | 99.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neumora Therapeutics
NMRA
$283M
| $28.5M | 0.72% |
2,071,450
| – | – |
|
27
Celldex Therapeutics
CLDX
$1.57B
| $27.3M | 0.69% |
+650,000
| New | +$27.3M |
|
|
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
| $27.3M | 0.69% |
1,999,249
+884,227
| +79% | +$12.1M |
|
|
LENZ
29
LENZ Therapeutics
LENZ
$1.12B
| $27.2M | 0.69% |
1,219,774
-7,318,672
| -86% | -$89 |
|
30
Atea Pharmaceuticals
AVIR
$275M
| $24.8M | 0.63% |
6,145,861
-850,000
| -12% | -$3.43M |
|
31
Alector
ALEC
$282M
| $24.4M | 0.62% |
4,056,548
| – | – |
|
|
32
Edgewise Therapeutics
EWTX
$1.54B
| $22.8M | 0.58% |
1,250,385
-2,242,809
| -64% | -$40.9M |
|
33
Nkarta
NKTX
$149M
| $21.6M | 0.55% |
+2,000,000
| New | +$21.6M |
|
34
Pharvaris
PHVS
$1.41B
| $20.8M | 0.53% |
900,000
| – | – |
|
35
Vaxcyte
PCVX
$4.17B
| $20.5M | 0.52% |
+300,000
| New | +$20.5M |
|
36
Madrigal Pharmaceuticals
MDGL
$9.7B
| $20M | 0.51% |
+75,000
| New | +$20M |
|
37
Avidity Biosciences
RNA
$6.12B
| $19.3M | 0.49% |
+757,576
| New | +$19.3M |
|
38
Ovid Therapeutics
OVID
$94.6M
| $18.7M | 0.47% |
6,117,400
| – | – |
|
|
VERV
39
DELISTED
Verve Therapeutics
VERV
| $16.6M | 0.42% |
1,250,000
| – | – |
|
40
Keros Therapeutics
KROS
$640M
| $12.4M | 0.31% |
+187,500
| New | +$12.4M |
|
41
Dyne Therapeutics
DYN
$1.92B
| $12.1M | 0.31% |
+427,039
| New | +$12.1M |
|
42
Kyverna Therapeutics
KYTX
$161M
| $11.2M | 0.28% |
+450,000
| New | +$11.2M |
|
43
Gossamer Bio
GOSS
$587M
| $10.9M | 0.27% |
9,195,404
| – | – |
|
|
KLRS
44
Kalaris Therapeutics, Inc. Common Stock
KLRS
$85.5M
| $8.53M | 0.22% |
+11,294,585
| New | +$8.53M |
|
45
Kodiak Sciences
KOD
$453M
| $8.49M | 0.21% |
+1,613,600
| New | +$8.49M |
|
46
Generation Bio
GBIO
$40.3M
| $8.33M | 0.21% |
2,046,867
| – | – |
|
47
Atara Biotherapeutics
ATRA
$88.7M
| $7.06M | 0.18% |
10,167,043
+100,000
| +1% | +$69.4K |
|
48
ProQR Therapeutics
PRQR
$256M
| $6.6M | 0.17% |
2,884,357
-95,659
| -3% | -$219K |
|
49
Aligos Therapeutics
ALGS
$75.1M
| $6.26M | 0.16% |
6,389,468
| – | – |
|
50
Arcutis Biotherapeutics
ARQT
$1.91B
| $4.96M | 0.13% |
+500,000
| New | +$4.96M |
|